Nuclear Medicine Communications · 1997 · 13 citations · 0 references
MedicineNuclear MedicineDiagnostic ImagingNeuropharmacologyNeuroradiologyBrain ImagingHuntington DiseaseNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseParkinsonian DisordersDopamine Receptor ImagingExtrapyramidal Motor SystemExtrapyramidal SignsExtrapyramidal SystemHuntington Disease ImagingNeuroimaging In Parkinson's DiseaseParkinson Disease ImagingParkinsonism Imaging
Single photon emission tomographic investigations of the extrapyramidal system have become easier to perform since the development of the ligands [123I]-beta-CIT and [123I]-IBZM. Thirty-three patients were investigated with [123I]-IBZM. The images were evaluated visually and semi-quantitatively (ratio of the striatum to front cortex). Ten controls showed a mean (+/- S.D.) ratio of 1.513 +/- 0.06; nine patients with Parkinson's disease had a smaller ratio of 1.425 +/- 0.095; six patients with Huntington's disease had a significantly lower ratio (1.147 +/- 0.105). Eight patients were not classified, because of different nosologic entities. Twenty-three patients were investigated with [123I]-beta-CIT. They were evaluated using standard techniques and the ratio of the striatum to cerebellum. Six controls had a mean ratio of 5.128 +/- 0.787. In 11 Parkinson patients, the ratio was significantly less (3.359 +/- 0.769). Patients with focal dystonia showed normal values. One patient with Huntington's disease had a significantly lower ratio. Receptor studies of the extrapyramidal system may help with diagnoses and could be of relevance therapeutically.